Looking at the Development Trend of ADC from World ADC
In recent years, the ADC field has seen frequent blockbuster transactions and layouts, showing a pattern of contention among a hundred schools of thought. Only
In recent years, the ADC field has seen frequent blockbuster transactions and layouts, showing a pattern of contention among a hundred schools of thought. Only
Recently, a senior Republican committee aide revealed to the media Endpoints News that although policy negotiations including additional provisions (accelerated approval of reforms, etc.) are
According to the FDA’s official website, the indications of three PARP inhibitors for the last-line treatment of ovarian cancer have been withdrawn, namely AstraZeneca’s olaparib,
On September 20, Merck announced that it would initiate a new Phase III clinical trial designed to evaluate once-daily oral administration of Islatravir (100 mg)
On September 20, Cidara/Melinta Therapeutics jointly announced that the FDA has accepted the New Drug Application (NDA) for rezafungin (rezafungin) for the treatment of candidemia
On September 19, 2022, Pfizer announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the oral JAK3/TEC
On September 19, Roche announced that the marketing application of the ophthalmic dual anti-Faricimab (Vabysmo) has been approved by the European Union for the treatment
On September 15, Jasper Therapeutics announced that its CD117 monoclonal antibody JSP191 has been granted Fast Track designation by the FDA for the treatment of
On September 14, MC2 Therapeutics announced that it had completed the first patient dosing of the Phase II MC2-25-C1 trial. The trial was designed to
According to the official website of the World Health Organization, on September 14, WHO Director-General Tedros Adhanom Ghebreyesus said at an online press conference that
On September 12, Pretzel Therapeutics, a biotechnology company, announced the completion of a $72.5 million Series A financing to pioneer innovative therapies that modulate mitochondrial
On Sept. 13, Rubius Therapeutics announced plans to restructure its operations and implement a series of cost-saving measures in order to advance its next-generation red